IDXX

IDEXX Laboratories, Inc. 2008 Annual Report (10-K) Summary

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2008. IDEXX Laboratories, Inc. develops, manufactures, and distributes diagnostic products and services primarily for the veterinary market, as well as for food and water testing and human point-of-care medical diagnostics. The company operates through four primary segments: Companion Animal Group (CAG), Water, Production Animal Segment (PAS), and Other (which includes Dairy and OPTI Medical). In the fourth quarter of 2008, the company sold its Acarexx and SURPASS veterinary pharmaceutical products and restructured the remaining pharmaceutical business, realigning product lines to the CAG and Other segments.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 11% to $1.024 billion. Growth was driven by organic sales increases across all segments, with CAG contributing the largest absolute increase ($83.6 million). Currency exchange rates had a favorable impact of 1% on total revenue.
• Profitability: Operating income increased 27% to $172.5 million. Gross margin improved to 51.7% from 50.2%, aided by lower costs for chemistry slides and favorable currency impacts, partially offset by higher instrument placement costs for new products.
• Debt Levels: Total debt more than doubled to $156.5 million, primarily due to increased borrowings under the company's revolving credit facility to fund share repurchases and capital expenditures. Borrowings under the credit facility increased from $72.2 million in 2007 to $150.6 million in 2008.
• Segment Performance:
  • CAG: Revenue grew 11% to $834.1 million. Growth was driven by instruments/consumables and laboratory services. Pharmaceutical product revenue was flat as the business was being divested.
  • Water: Revenue grew 12% to $74.5 million, driven by higher sales volumes of Colilert products.
  • PAS: Revenue grew 8% to $80.8 million, driven by livestock diagnostics sales and favorable currency impacts.

Guidance, Outlook, Risks, and Unusual Items

• Pharmaceutical Divestiture: The company sold its veterinary pharmaceutical products in Q4 2008. Future pharmaceutical revenue is expected to be negligible, with the company retaining only certain drug delivery technologies for licensing.
• Regulatory Headwinds:
  • Water: Effective January 1, 2009, testing for Cryptosporidium is no longer mandated in England and Wales, expected to result in a loss of approximately $2.8 million in annual sales of Filta-Max products.
  • PAS: EU regulations revised the BSE (mad cow disease) testing age requirement from 30 to 48 months, estimated to reduce the tested cattle population by 30%, negatively impacting post-mortem test sales.
• Economic Risks: Management highlighted risks related to the global financial crisis, including potential reductions in pet owner spending on veterinary care and tighter credit markets affecting customer financing.
• Capital Allocation: The company repurchased 2.64 million shares of common stock in 2008 for $132.3 million. Capital expenditures were $89.2 million, largely driven by the renovation and expansion of the Westbrook, Maine headquarters.
• Patent Expirations: A key patent covering FIV diagnostic products is set to expire in June 2009, which may lead to increased competition and margin pressure.

Investor Verification Checklist

• Debt Utilization: Verify the sustainability of the increased debt load ($150.6M outstanding) relative to operating cash flow and the impact of rising interest rates on the variable-rate credit facility.
• Regulatory Impact: Assess the actual financial impact of the 2009 regulatory changes in the UK (Cryptosporidium) and EU (BSE testing) on the Water and PAS segments.
• Pharmaceutical Transition: Confirm the timeline and financial realization of the retained pharmaceutical licensing arrangements and the integration of realigned product lines into CAG and Other segments.
• Supply Chain Concentration: Review the reliance on single-source suppliers, particularly Ortho-Clinical Diagnostics for chemistry slides, and the terms of the supply agreement extending to 2025.
• Patent Expiration: Monitor competitive landscape and pricing power for FIV/FeLV tests following the June 2009 patent expiration.